BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15705097)

  • 41. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
    Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
    Cheng L; Koch MO; Juliar BE; Daggy JK; Foster RS; Bihrle R; Gardner TA
    J Clin Oncol; 2005 May; 23(13):2911-7. PubMed ID: 15860849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic impact of lymphovascular invasion in radical prostatectomy specimens.
    May M; Kaufmann O; Hammermann F; Loy V; Siegsmund M
    BJU Int; 2007 Mar; 99(3):539-44. PubMed ID: 17155973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
    Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
    J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [PCNA and Ki-67 expression in locally confined renal adenocarcinoma. Relationship with various histopathologic variables and prognostic significance].
    Tejido Sánchez A; Sánchez Chapado M; Rosino Sánchez A; Passas Martínez J; Bethencourt Codes F; Ruiz Ramos P; Leiva Galvis O
    Arch Esp Urol; 2002 Apr; 55(3):257-65. PubMed ID: 12068757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy.
    Boorjian SA; Karnes RJ; Crispen PL; Rangel LJ; Bergstralh EJ; Sebo TJ; Blute ML
    J Urol; 2009 Jan; 181(1):95-104; discussion 104. PubMed ID: 19012937
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
    Smith JA; Chan RC; Chang SS; Herrell SD; Clark PE; Baumgartner R; Cookson MS
    J Urol; 2007 Dec; 178(6):2385-9; discussion 2389-90. PubMed ID: 17936849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natural history of biochemical progression after radical prostatectomy based on length of a positive margin.
    Ochiai A; Sotelo T; Troncoso P; Bhadkamkar V; Babaian RJ
    Urology; 2008 Feb; 71(2):308-12. PubMed ID: 18308109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy.
    Guzzo TJ; Vira MA; Neway W; Hwang WT; Tomaszewski J; VanArsdalen K; Wein AJ; Malkowicz SB
    Urology; 2007 Jun; 69(6):1147-51. PubMed ID: 17572204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction.
    Nordström B; Strang P; Bergström R; Nilsson S; Tribukait B
    Cancer; 1996 Nov; 78(9):1942-51. PubMed ID: 8909315
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic factors of persistently detectable PSA after radical prostatectomy.
    Naselli A; Introini C; Andreatta R; Spina B; Truini M; Puppo P
    Int J Urol; 2009 Jan; 16(1):82-6. PubMed ID: 19054168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.